CDK7 and ovarian carcinoma: In May 2017, a phase I clinical trial including advanced solid tumors was launched to assess the effectiveness of SY-1365, a CDK7 inhibitor derived from THZ1, in treating breast and ovarian cancer (Clopper and Taatjes, 2022[24]; Diab et al., 2020[30]).